Case Study: Digital Phenotyping — Harnessing AI & Unstructured Data to Revolutionize Life-Saving Diagnostics
How AI-driven EMR analysis helped identify high-risk cardiovascular patients and support earlier intervention.
Case Study: Linking Real-World Datasets to Identify Cost Drivers in Lung Transplantation
How a biotechnology company used real-world data analysis to uncover cost drivers and validate the economic impact of EVLP.
Why Real-World Evidence Is Reshaping the Economics of Drug Pricing
Real-world evidence is no longer just a regulatory checkbox—it’s a strategic driver of pricing, access, and payer engagement. Discover how leading life sciences teams are embedding RWE earlier to shape reimbursement strategy, optimize launch planning, and unlock value-based contracts.
Deal-Driven Policy, Direct-to-Patient Models, and State Momentum: Preparing for 2026
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
Payer Research: A Strategic Driver of ROI Across the Lifecycle
Design research payers can use: focus on real-world outcomes, durability, and total cost of care; bring payer input in early and often; and pressure-test access levers pre-launch. Turn strong science into coverage, reimbursement, and measurable ROI.
Unlocking the Value of RWE in Drug Pricing Decisions
In this featured presentation from the 2025 Evidence 360 Summit, Magnolia Market Access’s Beni Turner explores how RWE can be strategically integrated across the product lifecycle to drive more effective pricing and access outcomes.
Case Study: Using Real World Data to Estimate the Annual Incidence of a Rare Disease
This case study explores how a small pharmaceutical company utilized real-world evidence (RWE) to calculate the national incidence of a rare disease.
MFN Policy Executive Order: What It Means for Pricing, Distribution, and Biopharma Strategy
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
Frailty, Real-World Data, and the Access Imperative: A Q&A with Magnolia’s Mike Murphy
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
Issue Brief: Federal-Level Policy Solution to Reduce Costs for 340B Patients
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.